Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679042 · ClinicalTrials.gov registry record · Phase 3
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by CellTrans.
- Active
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00679042: Active Phase 3 study of Type 1 Diabetes Mellitus, sponsored by CellTrans.
NCT00679042 is a Phase 3 study of Type 1 Diabetes Mellitus that is active but no longer recruiting, run by CellTrans. The registered enrollment target is 21 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00679042, a Phase 3 study of Type 1 Diabetes Mellitus, is active but no longer recruiting, sponsored by CellTrans.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation, and medical treatment at UIC. Therefore, the primary purpose of the present Phase 3 clinical trial is to demonstrate the safety and efficacy of allogeneic islet transplantation in improving glycemic control in Type 1 diabetic patients using the UIC protocol that was developed and proven effective during the Phase 1/2 clinical trial.
Primary Outcome
Safety endpoints: Incidence and severity of events related to islet infusion, immunosuppression, and islet preparations
Conditions Studied
Interventions
- BIOLOGICAL Islets of Langerhans transplantation
Study Locations (1)
Illinois
- University of Illinois at Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-09-05 |
| Est. Completion | 2026-06-14 |
| Phase | Phase 3 |
What the registry record for NCT00679042 still lists
NCT00679042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Islets of Langerhans transplantation is the first listed.
NCT00679042 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00679042 about?
NCT00679042 is a clinical study titled "Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol". In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation, and medical treatment at UIC. Therefore, the primary purpose of the prese...
What is the current status of trial NCT00679042?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2007-09-05. Estimated completion is 2026-06-14.
What conditions does trial NCT00679042 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00679042?
The interventions under investigation include: Islets of Langerhans transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT00679042?
This trial is sponsored by CellTrans, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00679042 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00679042's enrollment target sits among peer trials
21 86th of 112 higher than 27 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
RECRUITING · Phase 3
-
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Pediatric Diabetics Type 1 Using InsuPatch
COMPLETED · Phase 3
-
Efficacy of Islet After Kidney Transplantation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI